Literature DB >> 29522388

Alzheimer dementia: Starting, stopping drug therapy.

Luke D Kim1,2, Ronan M Factora1,3.   

Abstract

Alzheimer disease is the most common type of dementia. Two classes of cognition-enhancing drugs are approved to treat the symptoms, and both have provided modest benefit in clinical trials. Psychotropic drugs are sometimes used off-label to treat behavioral symptoms of Alzheimer disease. All these medications should be continuously evaluated for clinical efficacy and, when appropriate, discontinued if the primary benefit--preservation of cognitive and functional status and a reduction in behaviors associated with dementia--is no longer being achieved.
Copyright © 2018 Cleveland Clinic.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29522388     DOI: 10.3949/ccjm.85a.16080

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  2 in total

1.  A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease.

Authors:  Dongju Zhao; Yuqing Tang; Xinjun Suo; Chaonan Zhang; Yan Dou; Jin Chang
Journal:  Innovation (Camb)       Date:  2021-09-01

2.  Use of Off-Label Drugs and Nutrition Supplements among Patients with Amyotrophic Lateral Sclerosis in Norway.

Authors:  Gard Aasmund Skulstad Johanson; Ole-Bjørn Tysnes; Tale L Bjerknes
Journal:  Neurol Res Int       Date:  2022-04-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.